IFF Lags Peers After Q3 Print as Options Calm Persists

IFF is the least crowded short among its closest specialty-chemicals peers, with 5.7% of its free float sold short, even as the stock shed 1.1% over the past week against a median gain of 3.3% across correlated names including SHW, PPG and RPM.

The gap in short positioning is worth noting in that peer context. SHW, PPG and RPM each gained 4% to 7% over the week while IFF drifted lower, yet short sellers have been covering rather than adding. Short interest in IFF dropped roughly 8% over the past month to 14.6 million shares, and the week-on-week move was similarly downward at minus 7.8%. A one-day uptick of 5% on November 3 looks more like noise around the earnings release than a renewed directional bet. Lending conditions remain loose: availability runs at 390%, meaning there are nearly four shares available to borrow for every one currently shorted, and cost to borrow at 0.42% is among the lowest readings of the past six weeks. The ORTEX short score of 55.5 is mid-range and has been drifting down from a peak near 58.6 in late October, consistent with shorts gradually reducing exposure rather than pressing the trade.

Options positioning reinforces the same picture from a different angle. The put/call ratio fell to 0.68 this week, nearly three standard deviations below its 20-day average of 0.77. That is close to the 52-week low of 0.59, and the contrast with October's reading of around 0.80 is sharp. Call demand has dominated into and through the Q3 release, an unusual degree of upside positioning relative to recent norms. The stock's 2.6% drop on Tuesday alone suggests the print did not fully deliver on what options traders had priced in, though the PCR has not yet corrected back toward its mean.

The Street entered the week broadly constructive. Oppenheimer raised its target to $108 from $95 on October 22 and Barclays lifted to $105 from $96 the prior week, both holding positive ratings. Citigroup trimmed fractionally to $100 but kept its Buy. The consensus mean sits at $97.47, leaving implied upside of around 6% from the current $92.18. EV/EBITDA has contracted roughly half a turn over the past 30 days to 17.6, and the price-to-book ratio has risen to 1.79, up 0.18 over the same period, reflecting the month's earlier rally rather than post-print strength. The EPS surprise factor score ranks in just the 16th percentile, and the 90-day EPS momentum score of 13 points to a pattern of estimates coming in ahead of what the company delivers. The bull case rests on operational improvement: return on capital nearly doubled to 5.32% over the past year. The bear case is straightforward: revenue is projected to fall around 5.6% following divestitures, and the restructuring story leaves limited top-line growth to offer at current multiples.

The one insider data point that stands out is from June, when director Paul Fribourg made two open-market purchases totalling 273,500 shares at around $74.28 to $74.49, a combined outlay of roughly $20.3 million. That was discretionary buying at prices well below where the stock trades now. Since then, the only SEC-reported activity has been sales by the CFO and the President of the Scent division in August, both at prices below current levels and both modest in scale. The 90-day net insider position is slightly negative, though the August sales are small enough that the June purchase remains the defining signal in the recent insider record.

The level to watch now is whether the post-earnings dip holds above the $90 area, where IFF traded before the October rally began, and whether the put/call ratio normalises back toward its 0.77 mean as the event risk passes.